Overview of Mucosta 20%

What is Mucosta 20%? (Rebamipide Ophthalmic Suspension)

Property	Description
Active ingredient	Rebamipide (INN)
Form	Ophthalmic Suspension (Eye Drops)
Pharmacological class	Mucin Secretagogue, Mucosal Protective Agent
Common use (General)	Stabilization of the Tear Film and Ocular Surface Protection
Origin	Synthetic Amino Acid Derivative

1. Identity and Origin: The Active Substance and Chemical Class

Mucosta 20% is a prescription-only therapeutic product containing the active ingredient Rebamipide (INN). This substance is a unique synthetic compound, chemically identified as a quinolinone derivative and an amino acid derivative. Its initial pharmacological recognition was established through its oral use as an anti-ulcer agent, highlighting a sustained capability to protect and interact with various mucosal surfaces. The ophthalmic form is a single-ingredient product, developed specifically for targeted topical administration to the eye's surface.

2. Pharmacological Classification and General Purpose

The medicine is categorized primarily as a mucosal protective agent and, more specifically, a mucin secretagogue. This classification implies a mechanism that focuses on restoring the body’s natural protective functions rather than simply providing a lubricating substitute. The compound enhances mucin secretion by the ocular conjunctival cells, thereby stabilizing the tear film and helping to resolve corneal epithelial damage. This indicates the medicine supports the eye's natural regenerative processes to improve overall surface health and comfort. This mechanism offers a distinctive approach compared to conventional tear substitutes.

3. Formulation Type and Composition (Suspension vs. Solution)

Mucosta is supplied as an ophthalmic suspension, meaning the active Rebamipide is finely dispersed within an aqueous vehicle rather than being fully dissolved. This formulation choice is utilized because the drug has limited solubility, and this specific format ensures that the active compound achieves prolonged retention on the ocular surface for maximized local effect. Rebamipide ophthalmic suspension is used to improve objective clinical signs of ocular surface health. The unique physical form of the medicine is designed to optimize the duration and efficacy of its protective effects on the eye.

What side effects are possible with Mucosta 20%?

The safety profile of Rebamipide, the active ingredient in Mucosta, is officially defined by regulatory documents across several major physiological systems.

Adverse Reaction Categories

Adverse events are formally classified by frequency and grouped into System-Organ Classes. Gastrointestinal symptoms, such as constipation, diarrhea, and abdominal distention, alongside hypersensitivity reactions like rash and pruritus, are among the effects listed in regulatory labeling.

Classification	Examples of Officially Documented Effects
Uncommon (0.1% to <5%)	Gastrointestinal symptoms, general hypersensitivity, increased AST/ALT.
Rare (<0.1% or Incidence Unknown)	Shock, Anaphylactoid Reactions, Leukopenia, Thrombocytopenia, Jaundice.

Serious Adverse Reactions and System-Specific Cautions

Official prescribing information explicitly documents the potential for rare but clinically significant adverse reactions affecting vital systems. These include severe Hepatic Dysfunction and Jaundice (signaled by increases in liver enzymes), as well as Leukopenia and Thrombocytopenia (decreases in white blood cell and platelet counts). These reactions require close monitoring according to regulatory standards.

Population-Specific Safety Notes

The official labeling notes the need for specific caution when using this medicine in certain populations:

Older Adults: Side effects may be observed more frequently in older adult patients.
Hepatic Impairment: The medicine must be administered with caution in individuals with pre-existing hepatic impairment due to the documented risk of exacerbating liver function abnormalities.
Pregnancy and Lactation: Use during pregnancy or lactation should only be considered if the therapeutic benefits outweigh any possible risk to the fetus or nursing child, as stated in regulatory safety documents.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Mucosta (rebamipide) does not extensively detail the clinical manifestations or specific treatment protocols for an acute, massive overdose scenario in the same manner as for high-toxicity medications. The regulatory focus is placed on the rapid recognition and management of severe adverse reactions that may occur.

Documented High-Risk Events and Required Actions

The following high-risk findings and required actions are highlighted in official documents for managing severe reactions, which necessitates immediate medical attention:

High-Risk Manifestation (As Documented)	Necessary Action (Regulatory-Derived)
Shock or Anaphylactoid Reactions	Discontinue the drug immediately and take appropriate measures.
Hepatic Dysfunction (Jaundice, increased AST/ALT)	Discontinue the drug immediately and take appropriate measures.
Blood Abnormalities (Leukopenia, Thrombocytopenia)	Discontinue the drug immediately and take appropriate measures.

Seeking Urgent Medical Help

Urgent medical assistance is required if there is any suspicion of massive ingestion or if a patient exhibits signs of the serious, clinically significant adverse reactions listed above. This includes monitoring for symptoms that may indicate shock, anaphylaxis, severe changes in blood count, or liver injury (jaundice). In these events, the drug must be discontinued, and the patient must receive prompt medical evaluation and supportive care, as stated in the official regulatory documentation. Treatment is focused on the management of symptoms and supportive measures.

Therapeutic Uses of Mucosta 20%

Quick Facts: Uses and Benefits

May assist in the management of gastric ulcers.
May support improvement of lesions in the gastric mucosa, such as erosion, bleeding, redness, and edema.
Is prescribed for acute gastritis and acute exacerbation of chronic gastritis.

Mucosta (rebamipide) is a prescribed agent used in the management of certain gastrointestinal conditions. Its primary therapeutic domains involve supporting the health and repair of the gastric lining.

The medication is used to address gastric ulcers. It is also administered to improve observable gastric mucosal lesions, including areas of erosion, bleeding, redness, or swelling, which may occur in the context of acute gastritis or when chronic gastritis experiences acute flare-ups. Clinical use indicates that the drug may assist in the repair process of these lesions.

Rebamipide may contribute to the management of these conditions by helping to support the integrity of the stomach's protective mucus layer. It is often used as a component of a larger treatment plan prescribed by a healthcare professional.

Regulatory References

Badan Pengawas Obat dan Makanan (BPOM) therapeutic overview

Eligibility and Restrictions for Use

The official regulatory profile for Mucosta 20% (Rebamipide Ophthalmic Suspension) defines eligibility based on a patient's allergy status, age, and reproductive status.

Populations That Must Not Use the Medicine

The medicine is contraindicated and must not be used by patients who have a known history of hypersensitivity or allergic reactions to the active ingredient, Rebamipide, or any of the inactive ingredients within the ophthalmic suspension. This is the sole absolute prohibition on the regulatory label.

Populations with Restricted or Limited Use

Adults: Use is established for the adult population.
Pediatric Patients: Safety and effectiveness have not been established for use in the pediatric population (children and adolescents).
Pregnancy and Lactation: Use is not recommended or should be approached with caution in women who are pregnant or are breastfeeding. Regulatory guidance advises that a decision should be made only if the therapeutic benefit is determined to outweigh the potential risks.
Elderly Patients: Use in this demographic is advised with special care or caution. No explicit restrictions on use are typically documented based on underlying hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Mucosta 20%

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Other ophthalmic solutions (timing-based interaction risk); Systemic agents (minimal interaction risk due to absorption profile).
Specific interacting medicines (if explicitly listed)	None are formally listed as contraindicated for co-administration.
Mechanistic basis of interactions (only if stated in label)	The systemic potential for metabolic interaction is low due to limited metabolism by hepatic enzymes, with the majority of the active substance being excreted unchanged.
Timing-based interaction rules (if applicable)	Co-administration with other ophthalmic solutions requires a mandatory separation of at least five minutes to prevent physical washout.
Population-specific interaction notes (if applicable)	In cases of severe renal impairment, altered clearance leads to higher plasma concentrations and a prolonged elimination half-life of the active substance.
Interaction-related restrictions	Alcohol use is advised against as excessive consumption may potentially increase the risk of systemic adverse effects associated with the active substance.

Interaction Classifications (High-Level)

Classification Type	Regulatory Basis (EMA / FDA / etc.)
Interaction severity classification (as defined in official documents)	Generally classified as having a Low Risk of Systemic Drug-Drug Interactions.
Regulatory basis	Statements are based on the documented pharmacokinetic profile of the active substance and the procedural administration constraints detailed in prescribing information.
Interaction-context constraints (as defined in official documents)	The key constraint is the procedural timing rule for concurrent use of eye drops.

Resulting Interaction Structure

Official interaction statements:

Co-administration with other ophthalmic solutions requires a mandatory separation period of at least five minutes to prevent physical washout.
The metabolic profile, characterized by limited hepatic enzyme involvement, results in a low potential for systemic drug-drug interactions.
Altered drug clearance in severe renal impairment may lead to increased systemic exposure of the active substance.
The bioavailability of the active substance is not affected by co-administration with food.

Connection to the overall interaction profile (3 sentences):

The overall interaction profile is defined by the negligible systemic absorption from the topical ophthalmic suspension, which inherently limits the potential for interactions that alter the systemic exposure of co-administered medicines. The only official interaction-related restriction is the timing-based rule required when administering multiple eye drops. All official pharmacokinetic data confirms a low propensity for metabolic interaction via the CYP450 system.

Mechanism of Action

Pharmacodynamic Mechanism of Action

This agent exerts its action through three primary mechanistic domains within the gastrointestinal mucosa. First, it acts as a modulator of the endogenous prostaglandin pathway by stimulating the synthesis and release of PGE2 and PGI2 from epithelial cells. This pathway modulation enhances the production of the mucus-bicarbonate layer and increases local microcirculation in the tissue. Second, the drug functions as a direct scavenger of Reactive Oxygen Species (ROS), thereby reducing oxidative stress and mitigating molecular damage to cell structures. This prevents the progression of chemical injury to the epithelial barrier. Third, the compound promotes the healing processes of the mucosal lining. It stimulates the proliferation and migration of epithelial cells and activates local growth factors (e.g., EGF). This facilitates the re-establishment of mucosal continuity and the maintenance of barrier function through enhanced tissue renewal.

Dosage and Administration Information

How to Use Mucosta 20% (Rebamipide)

Rebamipide is officially approved for administration via two distinct routes, necessitating adherence to separate dosing guidelines based on the product form: the 2% Ophthalmic Suspension (Mucosta 20%) for topical use and the 100 mg Oral Tablet for systemic use.

Official Administration Guidelines

Administration Detail	Ophthalmic Suspension (2%)	Oral Tablet (100 mg)
Route of Administration	Topical Ophthalmic	Oral
Standard Dosing	One drop per administration to the affected eye(s)	100 mg per dose
Dosing Frequency	Four times daily (QID)	Three times daily (TID)
Intake Condition	N/A	Can be taken with or without food
Typical Timing	Evenly spaced throughout the day	Typically scheduled morning, evening, and before bedtime
Duration Pattern	Used as part of a long-term treatment plan, with continuous use observed up to 52 weeks	Continued until healing of the target gastric lesions is achieved

Population-Specific Use and Restrictions

For the oral tablet, safety and effectiveness have not been established in the pediatric population. Furthermore, specific caution is necessary for patients with renal impairment, as pharmacokinetic data indicate the potential for higher plasma concentrations and a longer elimination half-life in this group.

Procedural Note

In the event of a missed oral dose, official procedural instructions state that two doses should never be taken at one time. If a dose is forgotten, it should be skipped if it is near the time for the next scheduled dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Mucosta 20%

Evidence for Use in Dry Eye Disease (Keratoconjunctivitis Sicca)

The most extensive evidence for Rebamipide ophthalmic suspension was studied for Dry Eye Disease (DED). This research exploring how symptoms change over time has relied on Randomized Controlled Trials (RCTs), where patients were randomly assigned to receive the medicine or an inactive vehicle (placebo), and the subsequent systematic reviews that summarize these findings. These trials were typically conducted during periods of increased symptom activity and applied in studies examining patient-reported experiences in adults.

Researchers examined outcomes related to physical discomfort and the physiological integrity of the eye's surface. Specifically, studies monitored the condition of the cornea and conjunctiva by measuring staining scores, which are used to evaluate epithelial damage. Research also examined Tear Break-Up Time (TBUT), which describes tear film stability. Patient-reported outcomes describing perceived discomfort, such as dryness, pain, and foreign body sensation, were also carefully monitored using validated questionnaires.

The findings describe patterns observed in the studies: trials reported measurements that indicated a change in corneal and conjunctival staining scores over time in the group receiving the medicine compared to the vehicle-treated group. Studies also reported patterns related to measurements of tear film stability in the observed populations, and research describes changes measured during the study period. While studies report how symptoms evolved in the observed populations, findings related to aqueous tear production volume, measured by the Schirmer test, often showed less pronounced patterns.

Research in Other Ocular Surface Conditions

Research exploring the medicine for other ocular surface conditions remains limited. This area was evaluated in small-scale prospective studies and case reports, rather than large RCTs. Studies have explored the medicine's application in conditions associated with acute or disruptive episodes, such as Persistent Corneal Erosion and certain types of epithelial disorders.

In these settings, research examined outcomes related to epithelial integrity and localized injury. Findings are based on groups where sample sizes were modest, and studies monitored the healing of epithelial damage and changes in localized symptoms. Research provides insight into short-term changes; however, the data for these specific, less common conditions remain insufficient. The evidence quality varies across studies, and these findings apply only to the populations studied.

Key Studies & References

A Multicenter, Open-Label, 52-Week Study of 2% Rebamipide (OPC-12759) Ophthalmic Suspension in Patients With Dry Eye

Frequently Asked Questions (FAQ)

Common questions about Mucosta 20% (FAQ)

Q: What is the main thing Mucosta 20% is prescribed for?

The official documentation for Mucosta 2% Ophthalmic Suspension indicates it is approved for the treatment of Dry Eye Disease (DED). The oral tablet form, which contains the same active ingredient (Rebamipide 100 mg), is approved for treating specific conditions of the stomach, such as gastric ulcers and mucosal lesions related to gastritis.

Q: Why is it called '20%'? What does that percentage mean?

This figure refers to the concentration of the active ingredient, Rebamipide, in the product. The ophthalmic suspension is described in official documents as a 2% concentration of the active ingredient. This figure indicates the strength of the medicine in the solution.

Q: Is Mucosta 20% considered a proton pump inhibitor (PPI)?

No, according to official classification. Mucosta is categorized as a cytoprotective and mucoprotective agent. Its mechanism is to stimulate the natural defensive factors of the body, such as the production of mucus and prostaglandins, which is distinct from how proton pump inhibitors (PPIs) work to reduce stomach acid.

Q: What is the difference between Mucosta 20% and other generic stomach drugs?

Regulatory information describes Mucosta's core function as cytoprotection, which involves protecting the stomach lining and promoting healing. Its primary mechanism involves stimulating the production of protective factors like mucus and reducing cell damage, rather than suppressing acid production.

Q: How is Mucosta 20% different from standard antacids like Tums?

Mucosta is a cytoprotective agent that helps to heal and boost the natural defenses of the stomach lining itself. Standard antacids work by directly neutralizing stomach acid, changing the pH level of the stomach contents.

Q: How quickly should I expect to notice anything after starting Mucosta 20%?

The time it takes to see a change in symptoms is tied to the underlying healing process, which can vary by condition and individual. The active substance in the oral tablet typically reaches its highest concentration in the blood around 2.4 hours after the dose is taken. The overall time required for the intended effect is dependent on the healing process and duration patterns described in official documents.

Q: How long does the effect of a Mucosta 20% dose typically last?

Pharmacokinetic studies show that the active substance in the oral tablet has an elimination half-life of approximately 1.94 hours. The drug's official mechanism involves promoting protective and healing actions on the gastric mucosa, which is a continuous process over the course of treatment, not limited only by the single-dose half-life.

Q: Is Mucosta 20% a preventive medication, or does it treat active conditions?

It is used for both purposes, according to official indications. The oral tablet is used to treat active conditions, such as gastric ulcers, and is also indicated for the management of potential stomach injury associated with Non-Steroidal Anti-Inflammatory Drug (NSAID) use.

Q: Why do some people take Mucosta 20% if they are also taking pain relievers?

The oral tablet form of the active ingredient (Rebamipide) is described in official product information as being indicated for managing the potential stomach injury associated with Non-Steroidal Anti-Inflammatory Drug (NSAID) use. This refers to protecting the stomach lining from certain damage caused by these types of pain relievers.

Q: Can Mucosta 20% be used by people with other chronic stomach issues?

Official regulatory approval is limited to specific conditions, such as gastric ulcers and mucosal lesions related to gastritis. The product information does not list broader chronic stomach issues as approved indications.

Q: Has Mucosta 20% been studied in combination with H. pylori treatments?

Rebamipide is not a primary treatment for H. pylori infections. However, research has explored combining Rebamipide with standard eradication regimens. These studies focus on the potential for the cytoprotective mechanism to complement the core treatment.

Q: Is Mucosta 20% approved for use in all countries?

Regulatory documents show that Rebamipide (the active ingredient) is widely approved and used in countries like Japan and various regions across Asia. Official information indicates that the product is not currently approved for use in the United States by the FDA for oral or ophthalmic use.

Q: Does Mucosta 20% require a doctor's prescription?

Yes, regulatory classifications state that Rebamipide (Mucosta) tablets are officially classified as a Prescription Drug (Rx) in the countries where it is approved.

Q: Does Mucosta 20% cause drowsiness or affect alertness?

Dizziness has been noted as a potential side effect of the oral tablet in some official product information. Official safety documents indicate that if dizziness is experienced, it may affect the ability to concentrate. Safety advice associated with the product mentions caution regarding activities like driving or operating machinery.

Q: Can Mucosta 20% be taken with common daily supplements like vitamins?

Official product labeling requires that patients provide a full list of all products, including over-the-counter medicines and dietary supplements, to the prescriber. This practice helps evaluate the potential for any interactions.

Q: Is it necessary to have regular check-ups while using Mucosta 20%?

Yes, close monitoring is required by regulatory standards due to the rare risk of serious adverse reactions like Leukopenia, Thrombocytopenia, and Hepatic Dysfunction (liver problems). Regulatory documents state that monitoring, which may involve blood work to check liver function, is required when there is a risk of serious adverse reactions.

Q: Do older adults (seniors) need to take Mucosta 20% differently?

While the dosage is generally the same, regulatory documents include a specific caution: side effects may be observed more frequently in older adult patients. The need for cautious monitoring is noted in official information due to the potential for side effects to be observed more frequently in this age group.

Q: Are there any known drug interactions that make Mucosta 20% less effective?

No systemic drugs are listed in official documents as decreasing the efficacy of the tablets. However, when using the ophthalmic suspension, a 5-minute separation from other eye drops is mandatory to prevent physical washout, which could reduce the drug’s intended effect.

How should Mucosta 20% be stored and disposed of?

Mucosta 20% (Rebamipide Ophthalmic Suspension) requires strict adherence to regulatory storage and disposal mandates, primarily due to its formulation as a single-use disposal preparation.

Official Storage and Handling Requirements

Condition	Regulatory Requirement
Container Type	Single-use disposal preparation (UD); Do not store the remainder after use.
Temperature/Freezing	Do not freeze the ophthalmic suspension.
Handling	The container must be shaken well for redispersion before application.
Child Safety	Keep out of the reach of children.

Disposal Instructions

Official labeling instructs patients to dispose of any medicine remaining in the container after use, as the product is not meant for storage once opened. For discarding expired or unused medicine, patients should consult a pharmacy or medical institution for proper guidance. The product must not be transferred to others.

Mucosta 20%